165 related articles for article (PubMed ID: 35708082)
1. Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.
Karati D; Mahadik KSR; Trivedi P; Kumar D
Anticancer Agents Med Chem; 2023; 23(4):383-403. PubMed ID: 35708082
[TBL] [Abstract][Full Text] [Related]
2. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
3. CDK9 keeps RNA polymerase II on track.
Egloff S
Cell Mol Life Sci; 2021 Jul; 78(14):5543-5567. PubMed ID: 34146121
[TBL] [Abstract][Full Text] [Related]
4. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
5. The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation.
Oqani RK; Kim HR; Diao YF; Park CS; Jin DI
BMC Dev Biol; 2011 Jun; 11():33. PubMed ID: 21639898
[TBL] [Abstract][Full Text] [Related]
6. Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition.
Toure MA; Koehler AN
Biochemistry; 2023 Mar; 62(6):1114-1123. PubMed ID: 36854448
[TBL] [Abstract][Full Text] [Related]
7. Targeting cyclin-dependent kinase 9 in cancer therapy.
Shen YL; Wang YM; Zhang YX; Ma SJ; Yang LH; Zhao CG; Huang XY
Acta Pharmacol Sin; 2022 Jul; 43(7):1633-1645. PubMed ID: 34811514
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo.
Pei Y; Du H; Singer J; Stamour C; Granitto S; Shuman S; Fisher RP
Mol Cell Biol; 2006 Feb; 26(3):777-88. PubMed ID: 16428435
[TBL] [Abstract][Full Text] [Related]
9. CDK9 as an Appealing Target for Therapeutic Interventions.
Eyvazi S; Hejazi MS; Kahroba H; Abasi M; Zamiri RE; Tarhriz V
Curr Drug Targets; 2019; 20(4):453-464. PubMed ID: 30362418
[TBL] [Abstract][Full Text] [Related]
10. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
11. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
12. Cellular control of gene expression by T-type cyclin/CDK9 complexes.
Garriga J; Graña X
Gene; 2004 Aug; 337():15-23. PubMed ID: 15276198
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
14. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.
Tamrakar S; Kapasi AJ; Spector DH
J Virol; 2005 Dec; 79(24):15477-93. PubMed ID: 16306619
[TBL] [Abstract][Full Text] [Related]
15. Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II.
Zhang J; Li G; Ye X
J Virol; 2010 Dec; 84(24):12619-27. PubMed ID: 20943989
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation by cyclin-dependent kinase-9 controls ubiquitin-conjugating enzyme-2A function.
Shchebet A; Karpiuk O; Kremmer E; Eick D; Johnsen SA
Cell Cycle; 2012 Jun; 11(11):2122-7. PubMed ID: 22592529
[TBL] [Abstract][Full Text] [Related]
17. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ; Welsh SA; Devlin JR; Barbieri E; Knight DA; Offley S; Bjelosevic S; Costacurta M; Todorovski I; Kearney CJ; Sandow JJ; Fan Z; Blyth B; McLeod V; Vissers JHA; Pavic K; Martin BP; Gregory G; Demosthenous E; Zethoven M; Kong IY; Hawkins ED; Hogg SJ; Kelly MJ; Newbold A; Simpson KJ; Kauko O; Harvey KF; Ohlmeyer M; Westermarck J; Gray N; Gardini A; Johnstone RW
Cell; 2021 Jun; 184(12):3143-3162.e32. PubMed ID: 34004147
[TBL] [Abstract][Full Text] [Related]
18. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
19. The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition.
Albert TK; Antrecht C; Kremmer E; Meisterernst M
PLoS One; 2016; 11(1):e0146648. PubMed ID: 26745862
[TBL] [Abstract][Full Text] [Related]
20. G-actin participates in RNA polymerase II-dependent transcription elongation by recruiting positive transcription elongation factor b (P-TEFb).
Qi T; Tang W; Wang L; Zhai L; Guo L; Zeng X
J Biol Chem; 2011 Apr; 286(17):15171-81. PubMed ID: 21378166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
